A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis.
A 65-year-old lady presented with decreased vision in her left eye (LE). Best corrected visual acuity (BCVA) was 1/20. Complete examination showed idiopathic juxtafoveal retinal telangiectasis associated with subretinal neovascularization and she was treated with intravitreal ranibizumab every month for three months in the LE. After four months, her BCVA increased to 3/10. Fluorescein angiography (FA) showed minimal leakage and optical coherence tomography (OCT) confirmed absence of intra- or subretinal fluid in the macula. Examinations were repeated monthly for another 12 months and showed no recurrence. Intravitreal ranibizumab showed promising results for subretinal neovascularization due to idiopathic juxtafoveal retinal telangiectasis. A prospective study with large series of patients and controls may be necessary in order to determine the effectiveness of this treatment.
Karagiannis
Dimitrios
D
Second Department of Ophthalmiatrion Eye Hospital, NHS, Athens, Greece.
Georgalas
Ilias
I
Ladas
Ioannis
I
Eustratios
Parikakis
P
Mitropoulos
Panagiotis
P
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006115:Greece; D006801:Humans; D000069579:Ranibizumab; D012160:Retina / Q000503:physiopathology; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D013684:Telangiectasis; D016896:Treatment Outcome; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab